Researchers at IRB Barcelona and IBEC achieve photo-switchable molecules to control protein-protein interactions in a remote and non-invasive manner.
These tools will serve as a prototype to develop photo-switchable drugs, whose effects would be limited to a given region and time, thus reducing the side effects on other regions.
The article, cover and “Very Important Paper” of Angewandte Chemie, is a highlighted result of the European project “OpticalBullet”, funded by the European Research Council (ERC) and in which the two institutes participate.
Researchers with the joint programme Institute for Research in Biomedicine (IRB Barcelona)- Barcelona Supercomputing Center (BSC) on Computational Biology, together with scientists at Center for Genomic Regulation (CRG) have discovered a hidden DNA structural code that provides novel insights on gene expression. The results are available in the electronic version of ...
• Headed by EMBL in Germany, the consortium “SyStemAge” seeks to identify the molecular mechanisms behind aging and the consequences of this process, and also to propose biomarkers to combat age-related diseases.
• The consortium involves clinical researchers, biologists specialized in two types of blood cancer, systems biologists, and biotech managers.
• Patrick Aloy, researcher at IRB Barcelona, will integrate the biological and clinical data to build dynamic maps of genes and proteins involved in the processes addressed in this study.
Each year about 330,000 Europeans are diagnosed with colorectal cancer, a disease with a mortality rate of 44%. Many of the new treatments fail in clinical assays, and colorectal cancer metastasis is largely incurable
The journal Cancer Cell ranks the article on colon cancer metastasis by Eduard Batlle and Elena Sancho among the best 10 in 2012.
A new technique from IRB Barcelona combines chemistry and biology to produce an exact copy of the natural molecule Thiocoraline.
Thiocoraline is a potent anti-cancer agent that is chemically very complex, isolated from a sea sponge in 1997 by the company PharmaMar.
• This is the first study that studies and quantifies 1,600 known adverse effects of drugs currently on the market.
• The scientists Miquel Duran and Patrick Aloy provide a description of the molecular processes responsible for more than 1,000 secondary effects.
• This knowledge, which is available to the scientific community, may be of great use to minimize and predict adverse effects during drug design.
IRB Barcelona scientists pave the way towards describing the conformation of proteins that do not have a defined structure
Structural and theoretical techniques are combined to develop new methodologies for the analysis of proteins
Joan Roig’s team collect three-dimensional information of protein complexes involved in cell division.
Collaboration between researchers at the Institut de Biotecnologia i de Biomedicina (IBB) of the “Universitat Autònoma de Barcelona”, the Institute for Biocomputation and Physics of Complex Systems in Zaragoza, and IRB Barcelona has led to the publication of the first scientific paper on data collected from the BL13-XALOC beamline of the Alba Synchrotron, located in Cerdanyola de Vallès, a facility that which allows scientists to obtain 3D structures of macromolecular complexes.
The team at IRB Barcelona headed by the research associate Joan Roig...